Journal Basic Info

  • Impact Factor: 1.995**
  • H-Index: 8
  • ISSN: 2474-1647
  • DOI: 10.25107/2474-1647
**Impact Factor calculated based on Google Scholar Citations. Please contact us for any more details.

Major Scope

  •  Pediatric Surgery
  •  Orthopaedic Surgery
  •  Colon and Rectal Surgery
  •  Robotic Surgery
  •  General Surgery
  •  Neurological Surgery
  •  Plastic Surgery
  •  Transplant Surgery

Abstract

Citation: Clin Surg. 2016;1(1):1064.Review Article | Open Access

The Management of Advanced Colorectal Carcinoma Having Failed Standard Therapy - An Immunologic Approach

Arlen M, Arlen P, Saric O, Dubeykovskiy A, Coppa G, Crawford JM, Conte C and Molmenti E

Department of Surgery, Division of Surgical Oncology, North Shore University Hospital, USA
Deptartment of Pathology, Division of Surgical Oncology, North Shore University Hospital, USA
Division of Surgical Oncology, Northwell Health System, Hofstra College of Medicine and Precision Biologics Inc, USA

*Correspondance to: Myron Arlen 

 PDF  Full Text DOI: 10.25107/2474-1647.1064

Abstract

Over the past 40 years all of the major improvement in management of solid tumor malignancies including those of colorectal cancer has been via introduction of newer chemotherapeutic agents. During this time, while there have been significant changes in response as well as duration of survival, curative responses have not been noted. An obvious approach is to employ the patients own immune system to bring the developing lesion under control. It appears that while the malignancy does behave as a foreign cell type which when properly identified by host immunity can be controlled, the level of immunogenic protein characterizing the tumor is present at level far below what is immunologically required. Our group has defined these proteins from pooled allogeneic tumor membranes and delivered them at the threshold level felt to be required. Here, in early FDA approved clinical trials, significant enhancement in survival was accomplished. Considering that on completion of these early trials, the FDA considered that such future preparations were too dangerous, realizing that certain unrecognized viruses could be present. In order to more clearly define the antigen, monoclonals were developed for immunopurification, but on careful examination of the end results, it appeared that it was the antibody response via ADCC that initiated antitumor activity. The first of the mAbs related to the more prevalent oncofetal protein, MUC5ac was produced GMP for clinical trials.

Keywords

Cite the article

Arlen M, Arlen P, Saric O, Dubeykovskiy A, Coppa G, Crawford JM, et al. The Management of Advanced Colorectal Carcinoma Having Failed Standard Therapy - An Immunologic Approach. Clin Surg. 2016; 1: 1064.

Search Our Journal

Journal Indexed In

Articles in PubMed

Antimicrobial Peptides: A Potential Therapeutic Option for Surgical Site Infections
 PubMed  PMC  PDF  Full Text
Automated Sagittal Craniosynostosis Classification from CT Images Using Transfer Learning
 PubMed  PMC  PDF  Full Text
View More...

Articles with Grants

Prevalence of Temporomandibular Disorders and Some of Its Risk Factors, According to the Diagnostic Criteria for Temporomandibular Disorders (DC/TMD)
 Abstract  PDF  Full Text
The Antibacterial Activity Comparison of Carbon-Based Nanofilm Coated Titanium Alloy and Co-Cr-Mo Alloy
 Abstract  PDF  Full Text
View More...